ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

EDEN Eden Research Plc

4.35
0.00 (0.00%)
31 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.35 4.20 4.50 4.35 4.35 4.35 41,771 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 1.83M -2.24M -0.0042 -10.36 23.2M
Eden Research Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 4.35p. Over the last year, Eden Research shares have traded in a share price range of 3.55p to 12.00p.

Eden Research currently has 533,352,523 shares in issue. The market capitalisation of Eden Research is £23.20 million. Eden Research has a price to earnings ratio (PE ratio) of -10.36.

Eden Research Share Discussion Threads

Showing 12201 to 12217 of 18125 messages
Chat Pages: Latest  497  496  495  494  493  492  491  490  489  488  487  486  Older
DateSubjectAuthorDiscuss
10/5/2022
11:04
Eden year end was 31st DecemberMost public companies post results within 3 monthsEden take six monthsWhy do Eden take so long?So that the CFO can come up with some more creative accounting that will get past the FCA.His success rate?Big fat zero.
ravenna23
10/5/2022
10:48
Edens record of exploiting opportunities is shocking. Zero sales. Distribution agreements, zero sales. Regulatory approvals, zero sales.Ramp, rinse, repeatGo back to the Cenkos boiler room
ravenna23
10/5/2022
10:03
Following today's RNS, a reminder of the biopesticides opportunity in the US

hxxps://www.edenresearch.com/food_for_thought/20/biopesticides_in_the_us

investingisatrickygame
10/5/2022
09:35
Progress 'towards' regulatory approvalLabel 'extension'Sales 'big fat nothing'The market has moved to a 'risk off' position. Boards like Eden can no longer rely on cheap money from shareholders to pay their excessive remuneration.No sales, no job.
ravenna23
10/5/2022
07:19
Regulatory update: Progress towards EPA approval and further authorisation in Italy

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and a plastic-free formulation technology for use in global crop protection, animal health and consumer products industries, announces that it has passed a key milestone in the US for the approval of its products, Mevalone® and Cedroz Ô . In addition, Eden's biofungicide, Mevalone®, has received authorisation for use on new crops in Italy for the control of the disease Botrytis cinerea, a destructive fungal pathogen affecting many plant species, as well as authorisation for use against additional fungal pathogens Powdery Mildew and Sclerotinia.

supersonico
09/5/2022
15:35
Canary Conclusions;

Within the currently released Pfizer documentation there appears to be some rather strange claims.

In brief summary, for those light on time:

10% of the ~44,000 phase 3 trial participants were recruited at one trial site in Buenos Aires over a three week period.

That recruitment required 250 pages of documentation per person = 1.125m pages of case report forms.

The Principal Investigator, Fernando Polack, was apparently in multiple places at the same time as this recruitment and is multiply funded by and connected to FDA and Gates Foundation.

Polack appears to have singlehandedly done this recruitment and paperwork.

Further trial participants came from a site, 4444, which does not appear to have existed.

supersonico
09/5/2022
15:14
Oh, BIG FAT ZERO
neutralpov
09/5/2022
15:14
The bid is at 4.5p for tiny volumes...

On the other side, 4.9p seems to stick, no matter what the volume (tested up to 1m shares).

Checking the book, and doing a bit of guesswork, an attempt to offload 17.5m now just might fetch £375K if one is lucky.

Were I in the position of needing to get rid of that many, I'd jump at this chance.

It will soon be only £100K

And then a BFZ

neutralpov
09/5/2022
15:08
lol at loony and forger above.

Care to glance at the SHARE PRICE?

You know, the 600 lb gorilla in the room?

It seems to think just exactly like I do.

TARGET PRICE: EDEN.L 0.00000p

neutralpov
09/5/2022
11:54
Michael Yeadon: ex-Pfizer vice chairman .. Corona vaccines batch scandal

The U.S. vaccine error reporting system VAERS recently published a set of tables showing which Covid 19 vaccine batch caused damage reports and at what frequency. According to ex-Pfizer vice chairman Dr. Michael Yeadon, there can only be strategic intent here, not mishap or even coincidence.

supersonico
06/5/2022
21:02
The Canaries last call..."The losses will be unprecedented."

GEERT VANDEN BOSSCHE: ‘MY FINAL CALL’

Yesterday, Geert Vanden Bossche, DVM, PhD, made a Final Call to Public Health authorities, the scientific community, and every person on earth, to take notice of the possibility that we may be on an irreversible path toward a catastrophic and unprecedented human event the world has never seen before.



Since the beginning, Dr Geert Vanden Bossche’s predictions have been highly accurate, and not once has he been wrong. His final warning is scary to say the least. The pandemic is anything but over.

supersonico
05/5/2022
17:52
Canary Conclusions;

Naomi Wolf: ‘The Lies Of Pfizer’

supersonico
05/5/2022
15:58
I'm struggling to keep pace with the "information" from the forger and the wh0re (both above).

Is a judgment from the Tel Aviv Court expected soon?

Has an RNS been issued to warn holders?

neutralpov
05/5/2022
12:10
So, supersonico, will EDEN's exposure therefrom put it directly into the grave?
neutralpov
05/5/2022
11:50
NEW - "The number of severe complications after vaccination against Sars-CoV-2 is 40 times higher than previously recorded by the Paul Ehrlich Institute (PEI)," a study with around 40,000 participants by the Berlin Charité concludes.
supersonico
05/5/2022
11:07
Fascinating to hear from Sipcam Oxon SpA and Amati AIM VCT plc.

;D

From the silence, I think it possible that Canaccord Genuity Group Inc is acting solely as an aggregator here. Views?

neutralpov
05/5/2022
11:02
The FACT that they cannot hide is that even for tiny volumes, the BUY price of this disgrace is currently 4.5p.

Any attempt to dump a reasonable quantity, the price plummets further. Try to offload even a measly 131,000 shares (that's more than all but three of the directors appear to 'own') and I betcha the share price will fall to 3.5p.

A dump in the low millions of shares will take it down to 1p.

But even less if they dither.

neutralpov
Chat Pages: Latest  497  496  495  494  493  492  491  490  489  488  487  486  Older

Your Recent History

Delayed Upgrade Clock